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 Summary  
There are currently no disease-modifying therapies for the neurodegenerative disorder 
Huntington’s disease (HD). This study identified novel thiazole-containing inhibitors of the 
deacetylase sirtuin-2 (SIRT2) with neuroprotective activity in ex vivo brain slice and Drosophila 
models of HD. A systems biology approach revealed an additional SIRT2-independent property 
of the lead-compound, MIND4, as an inducer of cytoprotective NRF2 (nuclear factor-erythroid 2 
p45-derived factor 2) activity. Structure-activity relationship studies further identified a potent 
NRF2 activator (MIND4-17) lacking SIRT2 inhibitory activity. MIND compounds induced 
NRF2 activation responses in neuronal and non-neuronal cells and reduced production of reactive 
oxygen species and nitrogen intermediates. These drug-like thiazole-containing compounds 
represent an exciting opportunity for development of multi-targeted agents with potentially 
synergistic therapeutic benefits in HD and related disorders.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Highlights 
* Novel thiazole-containing inhibitors of sirtuin-2 deacetylase identified   
* Lead-compound is neuroprotective in Huntington's disease models  
* Lead-compound is SIRT2-independent inducer of NRF2-dependent responses 
* Novel NRF2 inducers reduce levels of reactive oxygen and nitrogen species  
 
 
 
Introduction  
Mammalian NAD+-dependent sirtuin deacetylases (SIRT1-SIRT7) regulate diverse 
physiological functions in cells and are implicated as potential modifiers of age-related human 
diseases (Donmez et al, 2013). The second family member, sirtuin-2 (SIRT2), was originally 
identified as α-tubulin deacetylase (North, et al, 2003). Later studies, however, indicated that 
SIRT2 deacetylates a broad variety of protein substrates and regulates multiple cellular processes, 
including histone remodeling and gene transcription (Taylor et al, 2008; Rauh et al, 2013). SIRT2 
is a highly abundant protein in the adult CNS (Maxwell et al, 2011), including in neurons, 
although its precise function(s) remains uncertain (Maxwell et al, 2011; Luthi-Carter, 2010). We 
previously identified neuroprotective properties associated with several selective inhibitors of 
SIRT2 deacetylase (Chopra et al., 2012; Luthi-Carter et al., 2010; Outeiro et al., 2007). 
Huntington's disease (HD), an autosomal dominant and progressive neurodegenerative 
disorder, is caused by expansion of a polymorphic trinucleotide repeat sequence (CAG)n within 
the gene encoding the large, highly conserved protein, Huntingtin (HTT) (1993). The expression 
of mutant HTT induces complex pathogenic mechanisms and alterations in multiple cellular 
pathways, including but not limited to protein folding and clearance, transcriptional 
dysregulation, and mitochondrial dysfunction.  No single neurodegenerative mechanism has 
emerged as the predominant mechanism and this complex disease pathology challenges effective 
development of neurotherapies.   
The harmful role of oxidative stress has been described in both HD patients and in 
experimental models (Browne and Beal, 2006; Sorolla et al.), and is potentially due to inherent 
sensitivity of neurons to an excess of reactive oxygen species (ROS) (Johri and Beal, 2012; Li et 
al., 2010; Stack et al., 2008; Tsunemi et al., 2012). Excessive oxidative stress has also been 
implicated in the pathology of other age-dependent neurodegenerative disorders with high 
prevalence such as Alzheimer's and Parkinson's diseases (Moller, 2010; Quintanilla and Johnson, 
2009; Zadori et al., 2012). 
The initial goal of the present study was to identify a new scaffold(s) of potent and 
selective SIRT2 inhibitors and to assess the therapeutic potential of these compounds in models 
of neurodegenerative diseases (Chopra et al., 2012; Luthi-Carter et al., 2010; Outeiro et al., 2007; 
Pallos et al., 2008). We identified and characterized a novel structural scaffold MIND4, which 
transpired to contain compounds with dual SIRT2 inhibition and antioxidant NRF2  (nuclear 
factor-erythroid 2 p45-derived factor 2) activation properties.  
 
Results 
Identification of a lead series of novel SIRT2 inhibitors  
To identify novel SIRT2 inhibitors, a scaffold-hopping approach was taken. We used 
derivatives of 8-nitro-5-R-quinoline and 5-nitro-8-R-quinoline, previously identified as 
substructures of bioactive compounds, as starting templates to create an initial focused library for 
screening compound activities in biochemical acetylation assays with human recombinant SIRT2 
protein (Bodner et al., 2006; Outeiro et al., 2007). Compounds were screened at a single 
concentration (10 µM) in triplicate in biochemical SIRT2 assays and counter-screened against 
SIRT3 activity to assess target selectivity. Using iterative structure-activity chemical 
modifications to improve potency and selectivity, we identified compound 5-nitro-8-{[5-
(phenoxymethyl)-4-phenyl-4H-1,2,4-triazol-3-yl]thio}quinoline, henceforth MIND4 (Fig. 1A, 
B). In vitro activity tests of MIND4 showed selective concentration-dependent inhibition of 
human recombinant SIRT2 deacetylase activity (Fig. 1C-E). A structure-activity relationship 
(SAR) study identified additional thiazole analogs with selective SIRT2 inhibition activity, 
however with lower potency than the parent compound MIND4 (Fig.1G). Intriguingly, a close 
structural analog 5-nitro-2-{[5-(phenoxymethyl)-4-phenyl-4H-1,2,4-triazol-3-yl]thio}pyridine, 
henceforth MIND4-17 (Fig.1G), lacked any SIRT2 inhibition activity in the tested concentration 
range of 0.1-10 µM (Fig. 1F).  
 
Characterization of a selective SIRT2 inhibition mechanism of the lead inhibitor MIND4  
The precise potency of SIRT2 inhibition by MIND4 was determined as IC50=1.2±0.2 µM 
in a concentration-dependent activity test with human recombinant SIRT2 deacetylase (Fig. 2A). 
A subsequent mechanistic study revealed competitive inhibition with NAD+ and non-competitive 
inhibition with the peptide substrate with Ki of 2.1±0.2 µM (Fig. 2B, C). We used these results 
and molecular docking to generate a model of a SIRT2/MIND4 complex, which defines a 
molecular basis for compound selectivity against SIRT2 (Fig. 2D). The model shows partial 
MIND4 overlap with the NAD+ binding site but not with the acetyl lysine site. Superimposition 
of the complex with SIRT1 and SIRT3 shows that MIND4 fits the larger SIRT2 active site. 
SIRT1 isoleucine-316 (Ile316) and SIRT3 leucine-395 (Leu395) and the corresponding helices 
would clash with MIND4, providing a rationale for SIRT2 selectivity.  
 
Bioactivity of SIRT2 inhibitor MIND4  
The activity of MIND4 was tested in rat embryonic striatal ST14A cells stably expressing 
a 546 amino acid HTT fragment containing either a wild-type (26Q) or expanded (128Q) 
polyglutamine repeat (Ehrlich et al., 2001; Quinti et al., 2010). Consistent with the properties of a 
SIRT2 deacetylase inhibitor, MIND4 treatment increased acetylation of α-tubulin lysine-40 
(K40) in both wild-type and HD cells (Fig. 3A, B, C) (North et al., 2003). Next, MIND4 activity 
was examined in wild-type primary cortical neurons (DIV11), which preferentially express full-
length SIRT2 (isoform SIRT2.1) and are enriched in the brain SIRT2.2 isoform (Fig. 3E) 
(Maxwell et al., 2011). Transient 6 h treatment with MIND4 did not increase acetylation of 
cytoplasmic α-tubulin (K40), but upregulated acetylation of known nuclear H3 histone substrates 
lysine-56 and lysine-27; acetylation levels of lysine-14 of H3 histone were unchanged (Rauh et 
al., 2013), (Fig. 3 E, F).  An increase in histone acetylation suggests that such SIRT2 inhibition 
could influence gene transcription as reported in previous work (Luthi-Carter et al., 2010).  
 
Treatment with MIND4 is neuroprotective in HD models 
Next, rat corticostriatal brain slice explants were used to test the neuroprotective potential 
of MIND4 in a complex neural tissue system expressing HTT exon 1 with expanded CAG repeats 
(mHTTex1) (Reinhart et al., 2011). Treatment with MIND4 significantly protected against 
mHTTex1-induced neurodegeneration in a concentration-dependent manner (Fig. 3G). 
Neuroprotection at the highest 10 µM concentration of MIND4 was comparable to the efficacy of 
a reference compound, the pan-caspase inhibitor Boc-D-FMK (C) at 100 µM (Varma et al., 
2007). MIND4 was further tested in an additional in vivo setting using a Drosophila model of 
HD, in which neuroprotective effects of SIRT2 inhibition has been established in previous studies 
(Marsh et al., 2003; Pallos et al., 2008). In this model, degeneration of photoreceptor neurons is 
visually scored by the presence of surviving rhabdomeres in the eyes of Drosophila expressing 
mHTTex1 (Steffan et al., 2001). Flies treated with 10 µM MIND4 had significantly more 
surviving rhabdomeres than untreated controls (Fig. 3H). The neuroprotective effects of MIND4 
were confirmed in an independent second trial conducted at the 10 µM dose (data not shown). 
Relative rescue was estimated as 22.6% and 20.7% for the first and second trials, respectively.  
 
MIND4 induces transcriptional activation of the NRF2 pathway in HD and wild-type 
neuronal cells   
Next we sought to determine whether MIND4 treatment could alter gene expression, 
possibly restoring or compensating for transcriptional dysregulation in HD models as a possible 
neuroprotective mechanism (Crook and Housman, 2011; Luthi-Carter et al., 2002; Luthi-Carter et 
al., 2010). We thus performed gene expression profiling to determine the impact of MIND4 on 
transcriptional readouts in  wild-type and HD ST14A cells.   
Mutant HD and wild-type ST14A cells (Ehrlich et al., 2001; Quinti et al., 2010) were 
treated with MIND4 at 5 µM for 24 h. RNA from MIND4-treated and untreated HD mutant and 
wild-type ST14A cells was extracted and run on Affymetrix rat microarrays (Affy GeneChip Rat 
Genome 230 2.0 array) (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49392). 
Duplicates for each experimental condition were imported into Partek Genome Suite for 
biostatistical analysis. Genes showing significant differential expression were identified by 
ANOVA for three contrasts resulting in three gene-lists: mutant HD (MT) vs. wild-type (WT) = 
Case I (Disease Phenotype); MT/MIND4 treated vs. WT = Case II (Treatment Phenotype), and 
MT/MIND4 treated vs. MT = Case III (Mutant Drug-Dependent Phenotype)  (Table 1).  These 
represented transcriptional alterations in MT compared to WT cells (Case I), in MT treated 
compared to WT cells (Case II), and in MT treated cells compared to untreated MT cells (Case 
III). The lists, Cases I-III, were then imported into Ingenuity Pathway Analysis (IPA - Ingenuity 
Systems, www.ingenuity.com) for pathway and network analyses. 
Surprisingly, in treated MT cells compared to untreated MT cells (Case III), all top seven 
of the most significant canonical pathways activated by MIND4 treatment were either directly or 
indirectly related to NRF2; in decreasing order of significance, these were: 1) the NRF2-mediated 
oxidative stress response itself, 2) glutathione-mediated detoxification, 3) LPS/IL-1 mediated 
inhibition of RXR function, 4) aryl hydrocarbon receptor signaling, 5) xenobiotic metabolism 
signaling, 6) glutathione redox reactions, and 7) glutathione biosynthesis (Fig. 4A; please see 
Discussion for more details). Fig. 4B shows a portion of the IPA canonical pathway of NRF2 
colored by intensity correlated to fold-change of gene expression in treated versus untreated MT 
cells.  
Next we tested whether MIND4 could also induce transcription of ARE genes in primary 
neurons. Wild-type rat primary striatal neurons were treated with MIND4 at a 5 µM dose for 24 h 
and subjected to transcriptional microarray analysis as described (Luthi-Carter et al., 2010).  The 
analysis of transcriptional changes shows that treatment with MIND4 induced a robust expression 
of canonical NRF2 gene targets in primary neurons as well (Table S1, Supplemental 
Information).  
These results suggested the intriguing possibility that MIND4 is an inducer of NRF2, 
acting through a SIRT2 inhibition-dependent or -independent mechanism. 
 
MIND4 induces NRF2 activation response in SIRT2-independent manner  
To validate the transcriptional microarray data, wild-type and mutant HD ST14A cells 
were treated with MIND4 for 24 h, and the expression levels of two canonical NRF2-responsive 
proteins, NQO1 and GCLM, were examined. Concentration-dependent increases in these proteins 
were observed in both cell lines, consistent with activation of NRF2 (Fig. 5A, B).  
Next, we examined the effects of MIND4 on the stabilization of NRF2 protein, a well-
known step in the cascade of pathway activation. The effects of MIND4 on NRF2 levels were 
compared with the reference NRF2-inducer sulforaphane (SFP) (Kensler et al., 2007; Lee et al., 
2003; Zhang et al., 1992). Compounds were tested in COS1 cells transfected with plasmid 
constructs encoding NRF2-V5 proteins and β-galactosidase to normalize transfection efficiency 
between samples as described (McMahon et al., 2010). Treatment with both compounds resulted 
in stabilization of NRF2, as determined by the clear increases in protein levels (Fig. 5C). These 
results further support the finding that MIND4 is an inducer of the NRF2 pathway.  
Treatment with the structural analog MIND4-11, also a SIRT2 inhibitor (IC50=4 µM), had 
no effect on induction of the NRF2 response (Fig. 5D), further supporting a SIRT2-independent 
mechanism of NRF2 activation for MIND4. In contrast, treatment with the close structural analog 
MIND4-17, lacking SIRT2 inhibition activity, led to an even more potent induction of the NRF2-
responsive proteins NQO1 and GCLM compared to MIND4 in both wild-type and HD mutant 
ST14A cells (Fig. 5E, D). Together, the findings suggest that the parent compound MIND4 is 
also an inducer of NRF2, activating this pathway via a SIRT2 inhibition-independent mechanism.  
 Thiazole analogs MIND4 and MIND4-17 induces NRF2 activation response in primary 
mouse neurons and astroglia  
To extend evaluation of the NRF2 activation properties of MIND4 and MIND4-17 
analogs, compound effects were tested in primary mouse neurons. A concentration-dependent 
induction of NQO1 and GCLM proteins in wild-type mouse cortical neurons (6 DIV) treated with 
MIND4-17 for 24 h supported a direct induction of the NRF2 pathway (Fig. 6G). These results 
showed that treatment with MIND4-17 can induce canonical NRF2 activation responses in mouse 
neurons. 
Next, we examined whether MIND4-17 similarly to MIND4 could mediate 
transcriptional activation of canonical NRF2-responsive ARE genes.  To that end we first used an 
ARE response element transcriptional reporter assay in a rat corticostriatal neuronal co-culture 
system (Kaltenbach et al., 2010). As shown in Fig. 5H, MIND4-17 significantly increased the 
transcriptional rate of a 5x-ARE-luciferase reporter construct transiently transfected into 
corticostriatal co-cultures. As would be expected for direct activation of NRF2, an almost 
saturating transcriptional response was already observed within 4 h of compound treatment. 
Next, we determined whether MIND4-17 activates downstream ARE-dependent 
transcription of endogenous NRF2-target genes in native corticostriatal co-cultures. Treatment 
with MIND4-17 for 6 h significantly and concentration-dependently increased the expression of 
the canonical ARE genes Nqo1, Hmox1, Srx1, and to a lesser degree Gclc (Fig. 5I-L). These 
same genes were activated in primary rat neuronal cultures by MIND4 (Table S1). Finally, we 
compared the effects of MIND4 and MIND4-17 on transcriptional activation of NRF2 pathway in 
the context of the HD mutation. Both compounds showed similar concentration-dependent 
activation of the 5x-ARE-luciferase reporter in corticostriatal co-cultures derived from wild-type 
vs. an HD mutant knock-in mouse model (Q175/+) (Menalled et al., 2012).  Treatment of cultures 
with MIND4-17 for 24 h was not significantly cytotoxic for striatal (5 DIV) or cortical (5 DIV) 
neurons, differentially labeled in co-culture (Fig. S1). 
To extend the validation of NRF2 activation properties in non-neuronal cells, we tested 
MIND4 and MIND4-17 in primary mouse astroglia. Treatment with both compounds resulted in 
concentration-dependent increases of NRF2-responsive NQO1 and GCLM protein levels, 
demonstrating that effects of these inducers are not restricted to neuronal cells (Fig. 5O, P). 
 
NRF2 inducer MIND4 and its structural analog MIN4-17 reduce ROS levels in microglia 
We next performed functional studies evaluating properties of MIND4 and MIND4-17 in 
a well-characterized microglia model of NRF2 activation (Innamorato et al., 2008; Koh et al., 
2011) using lentiviral transduction of SIRT2 shRNA or a scrambled control (Fig. 6A). The effects 
of both compounds on the levels of reactive oxygen species (ROS) were examined in microglia 
activated with LPS/TNFα as described (Pais et al., 2013). Treatment with MIND4 or MIND4-17 
resulted in a decrease of ROS levels in wild-type microglia (Fig. 6B), Notably, the effect of 
MIND4-17 was more pronounced than the effect of MIND4 and in agreement with the difference 
in inducer potencies of NRF2 activation. SIRT2 knockdown in microglia caused a significant 
elevation of ROS levels as previously described (Fig. 6 B, C) (Pais et al., 2013). Nonetheless, 
treatment with MIND4-17 was still able to decrease ROS levels, albeit with lower magnitude than 
in wild-type microglia (Fig. 6C). The effects of MIND4 treatment on ROS levels were 
undetectable and likely due to its lower potency of NRF2 activation.  
Since SIRT2 knockdown led to an increase, not a decrease, in ROS levels in microglia 
(Pais et al., 2013), SIRT2 inhibitory activity of MIND4 is presumably irrelevant for the observed 
antioxidant effects of MIND4 in wild-type microglia. Moreover, the antioxidant effects of 
MIND4-17 in wild-type and SIRT2-null microglia are clearly independent from SIRT2 since this 
compound lacks SIRT2 inhibitory activity. Together, these findings indicate that the antioxidant 
effects of both MIND4 and MIND4-17 are attributable to the NRF2-activating properties of these 
compounds.  
 NRF2 inducers MIND4 and MIND4-17 reduce levels of reactive nitrogen intermediates 
(RNI) in microglia 
Finally, to determine whether NRF2 activation through a SIRT2-independent mechanism 
could be observed in activated microglia, the effects of MIND4 and MIND4-17 on neurotoxic 
nitric oxide, produced by microglial iNOS, were examined (Aguilera et al., 2007; Reynolds et al., 
2008; Tieu et al., 2003). Treatment with MIND4 and MIND4-17 reduced production of nitric 
oxide in a concentration-dependent manner in activated microglia, where the effect of MIND4-17 
was again more pronounced (Fig. 6 D). The reduction of nitric oxide levels was similar in control 
cell (white bars) vs. those transduced with SIRT2 shRNA (black bars), and irrespective of the 
presence or absence of SIRT2 inhibitory activity in MIND4 vs. MIND4-17, respectively. These 
results were again consistent with a SIRT2-independent mechanism for NRF2 activationn, here 
resulting in the reduction of nitric oxide levels in activated microglia.  
 
Discussion 
We have identified a novel scaffold of thiazole-containing compounds which exhibits 
selective SIRT2- inhibition activity at various potencies. Mechanistic studies with the most potent 
compound elucidated an NAD+-competitive mechanism of SIRT2 inhibition. MIND4 acts as a 
bioactive SIRT2 inhibitor, and is neuroprotective in ex vivo brain slice and in vivo Drosophila 
models of HD. Through a systems biology approach, we unexpectedly found that MIND4 is also 
a transcriptional inducer of the NRF2-mediated oxidative stress response and modulates multiple 
pathways (see Fig. 4A) all centrally regulated byNRF2 activation: in glutathione-mediated 
detoxification, NRF2 regulates the expression of multiple members of the glutathione transferase 
(GST) supergene superfamily, the enzymes that catalyse the conjugation of numerous xenobiotics 
with glutathione (Hayes and Dinkova-Kostova, 2014; Wu et al., 2012). In LPS/IL-1 mediated 
inhibition of RXR function, NRF2 binds directly to RXR through its Neh7 domain (Chorley et 
al., 2012; Wang et al., 2013). In aryl hydrocarbon receptor signaling, NRF2 is often required for 
induction of classical AhR battery genes, e.g. by dioxin (Yeager et al., 2009). In xenobiotic 
metabolism signaling, NRF2 regulates genes encoding multiple drug-metabolizing enzymes 
(Pratt-Hyatt et al., 2013; Wu et al., 2012). In glutathione redox reactions, NRF2 regulates the 
enzymes that are responsible for regenerating and keeping glutathione in its reduced state (Hayes 
and Dinkova-Kostova, 2014).  Finally, in glutathione biosynthesis, NRF2 regulates the expression 
of both subunits of the enzyme that catalyzes the rate-limiting step in glutathione biosynthesis 
(Moinova and Mulcahy, 1999). Moreover, MIND4 effects on gene transcription were confirmed 
to be translated into increased expression of NRF2-responsive proteins in both HD mutant and 
wild-type cells. Together, these results strongly implicate NRF2 as a central target of MIND4 
activation.  
The follow-up experiments with a close structural analog of MIND4, MIND4-17, 
suggested that the mechanism of NRF2 activation is SIRT2-independent. This conclusion was 
supported by results demonstrating similar effects of MIND4 and the known inducer SFP (Zhang 
et al., 1992) on stabilization of NRF2 protein, a well-defined step in the pathway activation by 
NRF2 inducers. A functional study showed that MIND4 and MIND4-17, the latter lacking 
detectable SIRT2 inhibition activity, both reduce production of ROS and RNI in microglia, 
consistent with the properties of NRF2 inducers. Together, these findings suggest that MIND4 
and MIND4-17 represent a novel class of NRF2 activators. 
The molecular mechanism of NRF2 activation was elucidated as targeting cytoplasmic 
KEAP1 adapter protein through covalent modification of major sensor-cysteine C151. That 
modification is resulted in conformational change and arrest of NRF2/KAEP1 complex, unable to 
target NRF2 for proteasome degradation, which leads to accumulation and nuclear translocation 
of de novo synthesized NRF2, and subsequent activation of ARE gene transcription. This NRF2 
activation mechanism is described in depth in an accompanying manuscript.  
Antioxidant activities mediated by the transcription factor NRF2 have emerged as a 
potential therapeutic approach to combat neurodegeneration and aging (Johnson et al., 2008; 
Joshi and Johnson, 2012; Lee et al., 2003; Lewis et al., 2012; Petri et al., 2012; Stepkowski and 
Kruszewski, 2011; Tufekci et al., 2011; van Muiswinkel and Kuiperij, 2005; Xiong et al., 2015). 
Overexpression of NRF2 provides protection for primary neurons from expression of mutant 
HTT fragment (Tsvetkov et al., 2013), and the efficacy of pharmacological activation of NRF2 
has been shown in HD mice and is associated with induction of broad antioxidant effects in brain 
(Ellrichmann et al., 2011; Stack et al., 2010).  
Therefore, the discovery of a novel drug-like scaffold of thiazole-containing compounds 
as described here presents an opportunity to develop clinical lead candidates with distinct as well 
as combined/synergistic mechanisms of SIRT2 inhibition and/or NRF2 activation.  
 
Experimental Procedures   
Compound source and storage  
Compounds were procured from ChemBridge Corp. San Diego (purity QC ensured by provided 
NMR), dissolved in molecular biology grade dimethyl sulfoxide (DMSO) to 10 mM stock 
concentration, aliquoted, and stored at -80 °C. Dimethyl fumarate was purchased from Sigma, 
dissolved to a 10 mM concentration in 100% DMSO, aliquoted and stored at -80 °C.  
MIND4-17 has also been re-synthesized (purity >95%) and has shown essentially identical 
potency of NRF2 activation as compound in multiple batches purchased from Chembridge. 
 
Characterization of compound-dependent inhibition of SIRT2 deacetylase activity  
Modulation of sirtuin activity by compounds was assessed using the Fluor de Lys fluorescent 
biochemical assay (BioMol International, LP) in a 96-well format as described (Outeiro et al., 
2007). Deacetylation reaction was performed at 37 0C for 1 h in the presence of human 
recombinant enzymes: SIRT1 (BioMol-SE-239) 1 unit/per reaction, SIRT2 (BioMol-SE-251) 5 
units/per reaction, or SIRT3 (BioMol-SE-270) 5 units/per reaction, compound of interest, 
standard buffer, 50 µM substrate, and 500 µM NAD+ according to the manufacturer's protocol.  
For analyzing the SIRT2 inhibition mechanism of MIND4 in a continuous coupled enzymatic 
assay with an α-tubulin peptide substrate, the recombinant enzyme was prepared and its 
activity analyzed as described previously (Moniot et al., 2013). The IC50 for MIND4 was 
determined using α-tubulin and NAD+ at 150 µM and 500 µM, respectively. The titration with 
NAD+ was performed at 150 µM α-tubulin peptide, and the peptide titration at 1 mM NAD+. 
Data analysis and fitting was done in Grafit 7 (Erithacus Software, Horley, UK). 
 
Docking model for selective binding of MIND4 to SIRT2 
For generating the SIRT2/MIND4 complex model, the compound was docked using the program 
FlexX of the LeadIT suite (BioSolveIT, Germany) and a SIRT2/ADP-ribose structure (PDB ID 
3ZGV) (Moniot et al., 2013); ligand omitted for the calculation) as the receptor. The MIND4 
molecule, generated as a 3D SDF file in MarvinSketch (ChemAxon, Budapest, Hungary), was 
docked with FlexX using default parameters, i.e., hybrid enthalpy and entropy driven ligand 
binding, hard penalty on protein ligand clashes (maximum allowed overlap volume 3.2 Å³), and 
average penalty on intra-ligand clashes (clash factor 0.6). The best pose was exported and 
visualized in Pymol (Schrödinger LLC, Portland, USA). The overlay with SIRT1 (PDB ID 
4KXQ) and with SIRT3 in complex with carba-NAD and acetylated peptide (PDB ID 4FVT) was 
generated using the build-in align command of Pymol. 
 
NRF2 stabilization assay  
COS1 cells were plated 16 h before transfection. Cells were co-transfected with plasmids 
encoding wild-type KEAP1 and NRF2-V5 (generous gifts from Dr. M. MacMahon and Dr. John 
D. Hayes, University of Dundee) at 1:1 ratio. A plasmid encoding β-galactosidase was transfected 
as well to monitor transfection efficiency. 24 h post-transfection cells were exposed to MIND4 or 
sulforaphane for 3 h, harvested, lysed, and extracts were prepared and loaded on SDS-PAGE 
normalized to β-gal expression activity.  Samples were resolved on SDS PAGE and 
immunoblotted with V-5 antibody.    
 
 
Rat embryonic striatal ST14A cells  
Compound bioactivity was tested in the rat embryonic striatal cell lines ST14A, which stably 
express either a mutant expanded repeat (128Q) or wild-type (26Q) 546 amino acid huntingtin 
(HTT) fragment (generous gift of E. Cattaneo) (Ehrlich et al., 2001). ST14A cells were 
propagated at 33 °C in the presence of serum. To induce neuronal differentiation cells were serum 
deprived and cultured at 37 °C in presence of N2 supplement (Invitrogen). Cells were treated 
with compounds concurrently with induction of neuronal differentiation for 24 h, unless stated 
otherwise, as described (Quinti et al., 2010).  
 
Protein extraction and Western analysis 
To assess protein levels, cell extracts were prepared, washed with PBS and lysed with buffer 
containing 2% SDS, Complete EDTA-free Protease Inhibitor Cocktail (Roche) and 1 mM 
phenylmethylsulfonyl fluoride (Sigma). Protein concentrations in cell extracts were evaluated 
using a BCA analysis kit (Pierce 23225) and normalized.  Samples were prepared in a SDS buffer 
containing DTT (New England Biolabs B7703S) and separated on bis-acrylamide protein gels via 
electrophoresis and transferred onto a 0.2 µm PVDF membrane (Bio-Rad 162-0177). Membranes 
were probed for NQO1 (Sigma N5288, 1:1,000), GCLM (Abcam ab126704, 1:800), SIRT2 
(Sigma S8447, 1:2,500), histone H3 (Cell Signaling 4499, 1:2,000), acetylated H3 (K56) 
(Millipore 04-1135, 1:500), acetylated H3 (K27) (Cell Signaling 4353, 1:800), acetylated H3 
(K9,K14) (Millipore 06-599, 1:10,000), GADPH (Millipore MAB374, 1:10,000), actin (Sigma 
A2066, 1:1250), α-tubulin (Sigma T6074, 1:10,000), and acetylated α-tubulin (Sigma T6793, 
1:2,500). Membranes were thrice washed in PBST for 15 min on a shaker and incubated in either 
an anti-rabbit-HRP (Bio-Rad 170-5046, 1:10,000) or anti-mouse-HRP (Sigma A3682, 1:4,000) 
secondary solution as appropriate in 3% milk in PBST for 1 h at room temperature on a rocker.  
After four washes of 15 min each in PBST on a shaker, blots were visualized using SuperSignal 
West Pico Chemiluminescent Substrate (Pierce 34080) or SuperSignal West Dura Extended 
Duration Substrate (Thermo 34075) and exposed on Scientific Imaging Film (Kodak 864 6770). 
Densitometric analyses of the Western blots were conducted using ImageJ software available 
from the National Institutes of Health, USA.  Blot intensities for proteins of interest were 
normalized to GADPH or α-tubulin levels. Statistical analyses were performed using a Student’s 
t-test.  
 
Microarray data analysis  
RNA was extracted from HD mutant and wild-type ST14A cells, differentiated for 24 h and 
treated with vehicle (DMSO) or with 5 µM MIND4, using the RNeasy kit (Qiagen). Labeled 
cRNAs were prepared and hybridized to Affymetrix GeneChip Rat Genome 230 2.0 microarrays 
according to the manufacturer's instructions. Affymetrix CEL (intensity) files from hybridized 
arrays were imported into the Partek Genome Suite, Partek Incorporated, for biostatistical 
analysis. 2 CEL files were used for each experimental condition: wild-type (WT) untreated, 
MIND4 treated (WT/MIND4), mutant (MTT) untreated, and mutant (MTT) MIND4-terated 
(MTT/MIND4). Two-way ANOVA was performed with interaction term included and evaluated 
three contrasts of interest (Case I, II, and III). Gene lists were created for each of the three 
contrasts using the thresholds of absolute value of fold-change > 1.5 and p-value with False 
Discovery Rate (FDR) < 0.05. The lengths of the gene lists are for Case I (DP)-1765 genes, for 
Case II (TP)-1797 genes, and for Case III (MDDP)-268 genes. These three gene lists were 
imported into Ingenuity IPA for pathway and network analyses. These analyses provided 
Networks (graph structures of molecules connected by relationships in the IPA knowledgebase), 
Functions (lists of molecules grouped together due to their contribution to a biological function) 
and Canonical Pathways (molecules and relationships that participate in a biological pathway). 
Scores are assigned according to the probability that the genes from the user’s list might appear in 
the function or pathway by chance (right-tailed Fisher’s Exact Test).  
 
Compound tests in acutely transfected rat brain slice culture assay   
Coronal brain slices (250 µm thick) containing both cortex and striatum were prepared from CD 
Sprague-Dawley rat pups (Charles River) at postnatal day 10 and placed into interface culture 
as previously described (Reinhart et al., 2011). All experimental procedures including the 
sacrificing of animals were done in accordance with NIH guidelines and under Duke IACUC 
approval and oversight. A biolistic device (Helios Gene Gun; Bio-Rad) was then used to co-
transfect the brain slices with YFP visual reporter and a mutant huntingtin plasmid containing 
human HTT exon-1 harboring a 73 CAG repeat to induce neurodegeneration of medium spiny 
neurons (MSNs).  MIND4 was added to cultures wells at the time of slice preparation and 
transfection to a final DMSO concentration of 0.1%; this concentration of DMSO was also added 
to all control wells.  The positive control used for these experiments was the pan-caspase inhibitor 
Boc-D-FMK (Sigma-Aldrich, Inc.) at 100 µM (Varma et al., 2007). YFP co-transfected MSNs 
were identified 4 days after incubation by their location within the striatum and by their 
characteristic dendritic arborization as previously described (Crittenden et al., 2010; Reinhart et 
al., 2011). Briefly, MSNs exhibiting normal-sized cell bodies, even and continuous expression of 
YFP within all cell compartments, and >2 discernable primary dendrites >2 cell bodies long were 
scored as healthy.  Ordinate axis expresses the mean numbers of healthy YFP-positive MSNs per 
striatal region in each brain slice.  Statistical significance was tested using ANOVA followed by 
Dunnett's post hoc comparison test at the 0.05 confidence level.  
 
Transcriptional assays in primary corticostriatal neuronal co-cultures 
Primary corticostriatal neuronal co-cultures were prepared from E18 WT or Q175/+ (Menalled et 
al., 2012) mouse brains as previously described (Kaltenbach et al., 2010). All experimental 
procedures including the husbandry and sacrificing of animals were done in accordance with NIH 
guidelines and under Duke IACUC approval and oversight. For 5x-ARE-luciferase reporter 
assays, neurons were transfected following their isolation (Nucleofector, Lonza) with 2.5 µg 
Cignal Antioxidant Response Reporter dual luciferase plasmids (Qiagen/SABiosciences) and 
plated onto pre-established glial beds in 96 well plates.  After 4 days in culture at 37 °C under 5% 
CO2, co-cultures were treated with the indicated compounds for 4 h or 16 h then harvested and 
read for luminescence from firefly and Renilla luciferases according to the Dual Glo luciferase 
protocol (Promega) using a SpectraMaxL luminometer (Molecular Devices).   Each sample was 
measured in technical triplicate.  For quantitative RT-PCR (qPCR) of ARE target genes, 
corticostriatal co-cultures were prepared as described above and, after 4 days in culture, treated 
for 6 h with the indicated compounds followed by RNA harvesting according to the Absolutely 
RNA miniprep protocol (Agilent Technologies).  Purified RNA was converted to cDNA using 
random hexamers and SuperScript First-Strand RT-PCR Synthesis (Invitrogen).  Resulting cDNA 
samples were used for qPCR using Power SYBR Green (Applied Biosystems) and the ViiA 7 
qPCR System (Applied Biosystems).   Ct values were determined using primer sets against ARE 
genes Hmox1, Srx, Gclc and Nqo1 (Yang et al., 2012).  Each sample was run in technical 
triplicate and relative expression expressed as fold-change over control after normalizing each 
sample to Ct values for GAPDH.   
 
Compound tests in a Drosophila model of HD  
Treatment of a Drosophila HD model with compound and efficacy analysis of the effects of 
MIND4 on photoreceptor neurons was performed as described (Pallos et al., 2008). The indicated 
numbers of flies were scored for each condition (n) with the number of ommatidia scored 
indicated in parentheses. Trial 1: DMSO=11(449); MIND4 1 µM=3(112); MIND4 10 
µM=9(337); MIND4 30 µM=9(364). Trial 2: DMSO=8(361); MIND4 10 µM=8(292). Relative 
rescue of photoreceptor neurons in flies treated vs. untreated with MIND4 at 10 µM dose was 
estimated for Trial 1 and Trial 2 as 22.6% and 20.7%; t-test significance for Trial 1 was p <0.001 
and for Trial 2 was p<0.02.  
 
Compound tests using ROS/RNI assays in stimulated microglia cells  
N9 microglial cells lentiviral-transduced with shRNA for SIRT2 knock-down or with a scrambled 
control shRNA were cultured in RPMI medium containing Glutamax (Invitrogen) and 
supplemented with 10% FBS (endotoxin levels lower than 10 EU/ml). Cells were plated in 96-
well plates (5x104/well) and cultured overnight before stimulation with LPS (100 ng/ml) and TNF 
(10 ng/ml) for 20 h in medium supplemented with DMSO or with the tested compounds. ROS 
levels were detected by flow cytometry after microglia incubation with 10 µM 5-(and-6)-
chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) 
(Invitrogen) for 20 min. The production of NO by iNOS was measured indirectly by assaying 
nitrites in the culture supernatant using the Griess reaction. Briefly, 100 µl of supernatants was 
incubated with an equal amount of Griess reagent (1% sulphanilamide, 0.1% 
naphthylethylenediamine in 2% phosphoric acid solution) and the absorbance read at 550 nm 
after 20 min of incubation at room temperature.  
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Table and Figure Legends 
Table 1 Legend. Gene expression analysis of MIND4-treated cells. Statistically significant 
expression changes of genes for Cases I-III. Genes highlighted in red are upregulated; genes 
highlighted in green are downregulated. Top seven Canonical Pathways are shown based on 
significance calculated by IPA for case III (MIND4-treated cells). 
Figure 1. Identification potent and selective SIRT2 inhibitor MIND4 . A, B) Primary and counter 
screening of focused library of 8-nitro-5-R-quinoline and 5-nitro-8-R-quinoline derivatives using 
SIRT2 (A) and SIRT3 (B) biochemical deacetylation assays. Compounds were screened at single 
10 µM concentration in triplicates. Selection of active inhibitors was set at indicated threshold 
(dotted lines) of <50% of SIRT2 remaining activity; >75% of SIRT3 remaining activity.  MIND4 
(compound #4) was preliminary identified as a potent selective SIRT2 inhibitor. C-E) 
Concentration-response tests in SIRT1 (C), SIRT2 (D) and SIRT3 (E) biochemical deacetylation 
assays showed a selective inhibition of SIRT2 by MIND4. F) Concentration-response activity test 
showed no detectable SIRT2 inhibition activity of structural analog MIND4-17. G) Structures 
and SIRT2 inhibition activities of MIND4 analogs. Compound SIRT2 IC50s were established in 
concentration-response tests in vitro.  
 
Figure 2. MIND4 mechanism of SIRT2 inhibition. A) Concentration-dependent inhibition of 
SIRT2 activity by MIND4. B-C) Competition of MIND4 with the SIRT2 co-substrate NAD+ and 
with acetylated substrate, respectively. Deacetylase activity of SIRT2 was measured at several 
MIND4 concentrations: 0 µM (empty circles), 0.625 µM (filled circles), 1.2 µM (empty squares), 
2.5 µM (filled squares), and 5 µM (triangles). Reactions were conducted at increasing 
concentrations of NAD+ (B) or peptide substrate (C). The best fitting inhibition model is 
competitive for NAD+ and non-competitive for the peptide substrate. D) Docking model of the 
SIRT2/MIND4 complex rationalizes isoform selective inhibition. Overlaid structures of SIRT1 
(yellow) (PDB ID 4KXQ), SIRT2 (blue) (3ZGV), and SIRT3 (pink) (4FVT) are presented as 
cartoons. MIND4, docked in SIRT2, is shown as balls-and-sticks in light blue. Acetylated lysine 
peptide and non-hydrolyzable NAD+ analog (carba-NAD+), shown SIRT3-bound, are presented 
as pink sticks. The large SIRT2 active site cavity is displayed as a transparent blue surface. 
 
 Figure 3. Bioactivity and neuroprotective properties of MIND4. A-B) MIND4 treatment 
increases acetylation of α-tubulin lysine-40 (K40) in wild-type (A) and HD mutant (B) rat 
embryonic ST14A cells. Cells were treated with compound for 6 h, then lysates prepared and 
resolved by SDS-PAGE, and immunoblotted with antibodies specific to acetylated K40 
acetylated and total α-tubulin. C) Quantification of α-tubulin acetylation from (A) and (B). Ratio 
of acetylated/total α-tubulin in wild-type (black line) and mutant HD (grey lane) was plotted 
against compound concentration. E-F) Effects of MIND4 on increase acetylation of SIRT2 
substrates, cytoplasmic α-tubulin and histone 3 (H3), in wild-type primary cortical mouse 
neurons (DIV 11) treated with compound for 6 h; protein levels analyzed by immunoblotting with 
respective antibodies.  E) Effects of MIND4 on acetylation of α-tubulin K40. Total α-tubulin 
levels were used as loading control. A putative compound target is preferentially expressed as a 
full-length SIRT2 protein (SIRT2.1 isoform). F) Effects of MIND4 on acetylation of H3 lysine-
56 (K56), lysine-27 (K27), lysine-9 and lysine-14 (K9/K14). Total H3 levels used as loading 
control. G) MIND4 treatment protects medium spiny neurons (MSNs) in rat ex vivo brain slices 
against toxicity of transiently transfected mutant (73Q) N-terminus HTT fragment (mHTTex1). 
Yellow fluorescent protein (YFP) was used as a neuronal viability marker and co-transfected with 
mHTTex1 constructs (black bars).  Effects are compared with survival of neurons expressing 
YFP plasmid alone (open bar) and expressed as the number of healthy YFP-positive MSNs per 
brain slice. MIND4 at the indicated concentrations (black bars) and the positive control pan-
caspase inhibitor Boc-D-FMK at 100 µM (grey bar) were added directly to the tissue culture 
media. Statistically significant effect of MIND4 treatment was observed at 10 µM by ANOVA 
followed by Dunnett's post hoc comparison test at the p<0.05 confidence level. H) MIND4 
enhanced survival of photoreceptor neurons in a Drosophila model of HD. Relative rescue of 
photoreceptor neurons, expressing mutant HTTex1 fragment, in flies treated vs. untreated with 
MIND4 at the10 µM dose was estimated as 22.6%. * = p <0.001.  
 
Figure 4. Gene expression profile and IPA analysis. Gene expression profiling and IPA analysis 
revealed NRF2 as the major pathway impacted by MIND4 in mutant HTT-expressing cells (Case 
III).  A) Pathway analysis resulted in lists of IPA “Canonical Pathways,” sorted according to 
Fisher's exact test right-tailed p-value.  The top Canonical Pathway was the NRF2-mediated 
Oxidative Stress Response. This pathway had a highly significant log(p-value) = 13.496. Other 
pathways are shown in decreasing order of significance to the right. The orange boxes are ratios 
of the number of MIND4 affected genes in the pathway to the total number in the pathway 
altogether. B) In Case III a fold-change increase of expression of NRF2-responsive genes is 
shown as a function of color intensity. Large fold-changes are shaded with dark red and 
decreasing values are shown in lighter red. The pathway shows differential expression in NRF2 
downstream targets in mutant HTT expressing cells in the presence and absence of MIND4.   
 
Figure 5. NRF2 activation properties of thiazole analogs MIND4 and MIND4-17. A-B) 
Treatment with MIND4 increased expression of NRF2-responsive proteins NQO1 and GCLM in 
wild-type (A) and in HD mutant (B) rat embryonic ST14A cells. Levels of GAPDH were used as 
loading control. C) Treatment with MIND4 increased stability of NRF2. COS1 cells were co-
transfected with plasmids encoding NRF2-V5, KEAP1, and β-galactosidase to monitor 
transfection efficiencies, and treated for 24 h with MIND4 at 10 µΜ or the classical NRF2 
inducer sulforaphane (SFP) at 5 µM. Cell extracts were prepared, proteins were resolved on SDS-
PAGE, and NRF2 levels were detected by immunoblotting with a V5 antibody. D) Comparative 
analysis of NRF2 activation response of NQO1 expression by the SIRT2 inhibitors MIND4 and 
MIND4-11 in HD mutant ST14A cells. Cells were exposed to compounds for 24 h. Levels of α-
tubulin were used as loading control. E, F) Treatment with MIND4-17 for 24 h increased 
expression of the NRF2-responsive proteins NQO1 and GCLM in wild-type (E) and in HD 
mutant (F) ST14A cells. Levels of GAPDH used a loading control. G) Concentration-dependent 
induction of the NRF2-responsive proteins NQO1 and GCLM in wild-type mouse cortical 
neurons (6 DIV) treated with MIND4 or MIND4-17 as indicated for 24 h. Protein expression was 
detected by immunoblotting. Levels of α-tubulin were used as loading control. H) Treatment of 
primary mouse corticostriatal co-cultures with 5 µM of MIND4-17 induced time-dependent 
increases in the transcriptional rate of a 5x-ARE promoter-luciferase reporter.  *p<0.05 by a 
Student’s t-test with respect to DMSO-only controls. I-L) MIND4-17 induces concentration-
dependent increases in transcription of the ARE genes Nqo1 (I), Hmox1 (J) Gclc (K), and Srx1 
(L) as quantified by qPCR.  *p<0.05 by a Student’s t-test with respect to DMSO-only controls 
(“0”). M, N) Similar concentration-dependent increases in the transcription of a 5x-ARE-
luciferase reporter transfected into wild-type (light grey) vs. mutant HD Q175/+ mouse neurons 
(black) in corticostriatal co-cultures were induced by treatment with MIND4 (M) and MIND4-17 
(N) for 24 h. *p<0.05 by a Student’s t-test with respect to DMSO-only controls (“0”).  O-P) 
Concentration-dependent induction by MIND4 (O) and MIND4-17 (P) of the NRF2-responsive 
NQO1 and GCLM proteins in primary mouse astroglia. Cultures were treated for 24 h with 
MIND4 or MIND4-17 at indicated concentrations. GFAP protein levels were used as the loading 
control. 
 
Figure 6. NRF2 activating properties of MIND4-17 in microglia cells with intact or knocked 
down SIRT2 protein. NRF2 activation properties were tested functionally by measuring 
production of reactive oxygen species (ROS) and reactive nitrogen intermediates (RNI) in 
LPS/TNFα induced microglia.  A) N9 microglial cells were lentivirally-transduced with shRNA 
for SIRT2 knock-down (sh2.1) or with a scrambled control shRNA (shCtr). SIRT2 levels were 
detected by immunoblotting. B-C) ROS levels in stimulated microglia with intact SIRT2 (B) or 
after SIRT2 knockdown (C) treated with vehicle (DMSO), MIND4 or MIND4-17. Microglia cells 
were stimulated with LPS and TNF for 20 h in medium supplemented with compounds at the 
indicated concentrations. Representative histograms of the fluorescence intensity for the ROS 
probe showing the overlays of vehicle (DMSO)-treated cells (filled light gray), treated with 
MIND4 (5 µM) (dotted line) or with MIND4-17 (2.5 µM) (filled dark gray). D) RNI production 
in stimulated microglia cells with functional SIRT2 (white bars) and SIRT2 knockdown (black 
bars). Cells were treated with vehicle (DMSO), MIND4, and MIND4-17 at the indicated 
concentrations. RNI was assessed by measurement of iNOS-dependent release of nitrites in the 
culture supernatants and quantified as percent of control (DMSO-treated cells). Data are 
presented as mean ± SD of four independent experiments. *p<0.05 and **p<0.01 by a Student's t-
test. 
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Table S1  
Gene Log  
Fold Change 
P value FDR Adj 
P value 
GCLC 1.42 2.54E-08 9.99E-07 
GCLM 2.32 1.48E-12 2.87E-09 
GSTA3 1.31 3.25E-05 0.00057 
GSTP1/GSTP2 1.60 2.13E-09 4.60E-07 
HERPUD1 1.98 3.98E-11 3.53E-08 
HMOX1/HO-1 4.20 1.45E-17 4.51E-13 
NQO1 2.03 4.93E-11 3.93E-08 
SRX1 2.40 3.90E-15 4.04E-11 
SQSTM1 1.25 2.20E-09 4.70E-07 
SOD1 0.83 6.65E-05 1.10E-06 
 
Table S1. (Associated with Figure 2). NRF2-responsive genes show increased transcription in 
wild type rat primary striatal neurons following treatment with 5 µM MIND4 for 24 h. 
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Fig. S1. (Associated with Figure 5). A-B) Treatment with MIND4-17 at indicated tested 
doses for 24 h is not cytotoxic for primary mouse striatal (A) and cortical (B) neurons in co 
culture with astroglia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extended Experimental Procedures 
Primary striatal rat neuronal cultures 
Primary neuronal cultures were prepared from mechanically dissociated ganglionic eminence 
tissues of wild-type rat embryos embryonic day 16 (E16). This procedure results in a predominant 
population of Neuronal nuclear antigen (NeuN)-positive and DARPP-32-positive neurons with 
some astroglia (Runne et al., 2008). Treatments of cultures with MIND4 were at 5 µM, whereas 
control cultures treated with vehicle (DMSO) only. RNA was extracted by using the RNeasy 
system (Qiagen), following the manufacturer’s protocol. Gene expression changes were assessed 
by microarray analysis as described previously (Luthi-Carter et al., 2010). 
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